Technical Analysis for AEZS - AEterna Zentaris Inc.

Grade Last Price % Change Price Change
grade D 1.09 1.87% 0.02
AEZS closed up 1.87 percent on Friday, January 17, 2020, on approximately normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Up
Historical AEZS trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Shooting Star Candlestick Bearish 1.87%
Calm After Storm Range Contraction 1.87%
Wide Bands Range Expansion 1.87%
Calm After Storm Range Contraction 1.87%
Wide Bands Range Expansion 1.87%
Up 3 Days in a Row Strength 1.87%
Up 4 Days in a Row Strength 1.87%
Calm After Storm Range Contraction 2.83%
Wide Bands Range Expansion 2.83%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Aeterna Zentaris Inc. a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for oncology and endocrine therapy primarily in Switzerland, the United States, and Japan. It markets Cetrotide, a luteinizing hormone-releasing hormone antagonist treatment for in vitro fertilization. The company's product pipeline includes AEZS-108, which is in Phase III clinical trial for the treatment of endometrial cancer, as well as in Phase II clinical trial to treat triple-negative breast, ovarian, castration and taxane resistant prostate, and refractory bladder cancers; and AEZS-130, an oral diagnostic test that has completed Phase III clinical trial for adult growth hormone deficiency, as well as in Phase IIA clinical trial for the treatment of cancer-induced cachexia. Its product pipeline also comprise Ozarelix, which is in Phase II clinical trial for the treatment of prostate cancer; Perifosine that is in Phase I/II clinical trials for the treatment of neuroblastoma, glioma, and pediatric solid tumors; and AEZS-112 an oral anticancer agent, which has completed Phase I clinical trial for the treatment of solid tumors and lymphoma. In addition, the company's products in preclinical development consist of AEZS-120, a live recombinant oral tumor vaccine candidate for the treatment of prostate cancer; AEZS-129, 134, and 136 PI3K/Erk inhibitors for oncology; and AEZS-137 and AEZS-125 for oncology. Aeterna Zentaris Inc. was founded in 1990 and is headquartered in Quebec City, Canada.
Chemistry Biopharmaceutical Cancer Treatment Of Cancer Oncology Solid Tumors Prostate Cancer Lymphoma Peptides Neuroblastoma Glioma Treatment Of Prostate Cancer Gnrh Antagonists Anthracyclines Endometrial Cancer In Vitro Fertilization Ozarelix

Is AEZS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 5.57
52 Week Low 0.76
Average Volume 130,717
200-Day Moving Average 2.09
50-Day Moving Average 0.92
20-Day Moving Average 0.95
10-Day Moving Average 1.04
Average True Range 0.07
ADX 38.83
+DI 32.10
-DI 9.89
Chandelier Exit (Long, 3 ATRs ) 0.94
Chandelier Exit (Short, 3 ATRs ) 0.97
Upper Bollinger Band 1.16
Lower Bollinger Band 0.73
Percent B (%b) 0.84
BandWidth 45.52
MACD Line 0.05
MACD Signal Line 0.03
MACD Histogram 0.0192
Fundamentals Value
Market Cap 17.56 Million
Num Shares 16.1 Million
EPS -1.71
Price-to-Earnings (P/E) Ratio -0.64
Price-to-Sales 28.12
Price-to-Book 6.12
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.17
Resistance 3 (R3) 1.16 1.13 1.15
Resistance 2 (R2) 1.13 1.11 1.13 1.15
Resistance 1 (R1) 1.11 1.10 1.12 1.12 1.14
Pivot Point 1.08 1.08 1.09 1.08 1.08
Support 1 (S1) 1.06 1.06 1.07 1.07 1.04
Support 2 (S2) 1.03 1.05 1.03 1.03
Support 3 (S3) 1.01 1.03 1.03
Support 4 (S4) 1.02